CHAP
2022
Chronic Hypertension and Pregnancy trial
In 2,408 pregnant women with mild chronic hypertension, antihypertensive treatment targeting a blood pressure below 140/90 mmHg reduced severe pre-eclampsia, medically indicated preterm birth, placental abruption or fetal or neonatal death compared with treatment withheld unless blood pressure reached 160/105 mmHg.
Result
Efficacy: Composite of pre-eclampsia with severe features, indicated preterm birth before 35 weeks, placental abruption, or fetal or neonatal deathadjusted RR 0.82 (95% CI 0.74-0.92) · P < 0.001
Below 1 favours antihypertensive treatment targeting a blood pressure below 140/90 mmHg, above 1 favours treatment withheld unless blood pressure reached 160/105 mmHg.
- Absolute difference
- 6.8 points
- NNT
- 15
Absolute difference and NNT are derived from the event rates.
Also reported: With no increase in small-for-gestational-age birth weight (11.2 % vs 10.4 %).
- Subtopic
- Hypertension in pregnancy
- Design
- Open-label RCT
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Tita AT, Szychowski JM, Boggess K, et al. N Engl J Med. 2022;386(19):1781-1792.doi 10.1056/NEJMoa2201295
Discussion & critique
Open-label with a partly clinician-adjudicated composite, and the benefit is driven by pre-eclampsia rather than hard neonatal outcomes. But it answered the fetal-growth question that had paralysed practice for decades: treating to below 140/90 mmHg does not cause growth-restricted babies, and shifted mild chronic hypertension from permissive to active treatment.